Results of Implantation of a New Hydrophobic Acrylic Monofocal Intraocular Lens in a Preloaded Injector

Abstract

Purpose. To evaluate clinical and functional results of implantation of a new hydrophobic acrylic monofocal IOL in a preloaded injector.Methods. The prospective study included 60 patients (66 eyes) after Hoya iSert® 250/251 IOL implantation (31 patients, 35 eyes, group 1) and a new Hoya Vivinex Multisert® XY1-SP IOL (29 patients, 31 eyes, group 2). The mean age was 75.1 ± 7.9 years. The mean follow-up period after surgery was 3.1 ± 0.4 months. IOL viscoimplantation was performed in 100 % of cases in group 1, in group 2 — in 45.1 % of cases, and in 54.9 % — hydroimplantation was performed. Intraoperatively, the size of the corneal incision was measured with a ruler before and after IOL implantation. IOL optic power was calculated with SRK/T and Barrett Universal formulas. In the postoperative period, surgically induced astigmatism was assessed.Results. In both groups, there was a statistically significant (p < 0.05) increase of UCDVA from 0.28 ± 0.09 in the preoperative period to 0.70 ± 0.17 3 months after surgery in group 1 and from 0.24 ± 0.10 in the preoperative period to 0.84 ± 0.18 3 months after surgery in group 2. Slightly lower values of UCDVA in group 1 may be associated with a higher level of SIA in this group. Similar dynamics were shown for the BCDVA (from 0.52 ± 0.21 before surgery to 0.95 ± 0.19 after 3 months of follow-up in group 1 and from 0.55 ± 0.20 before surgery to 0.98 ± 0.21 after 3 months of follow-up in group 2). No differences were found between the studied groups. After IOL implantation, there was an increase in incision size to 2.40 ± 0.12 mm in group 1 and 2.10 ± 0.08 mm in group 2 (p = 0.04). In group 1, the mean SIA after 3 months of observation was 1.10 ± 0.16 D and in group 2, 0.48 ± 0.07 D (p = 0.0007).Conclusion. This study presents the first domestic experience with the implantation of a new monofocal hydrophobic acrylic Hoya Vivinex IOL in a Multisert® preloaded injector. A comparative analysis of implantation results with monofocal Hoya 250/251 IOLs in an Isert® injector was performed. The advantage of the new IOL implantation in reducing the incidence of surgically induced astigmatism was shown.